These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155 [TBL] [Abstract][Full Text] [Related]
6. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model. Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700 [TBL] [Abstract][Full Text] [Related]
7. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M Front Immunol; 2022; 13():794684. PubMed ID: 35720386 [TBL] [Abstract][Full Text] [Related]
8. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Damsky W; Jilaveanu L; Turner N; Perry C; Zito C; Tomayko M; Leventhal J; Herold K; Meffre E; Bosenberg M; Kluger HM J Immunother Cancer; 2019 Jun; 7(1):153. PubMed ID: 31200747 [TBL] [Abstract][Full Text] [Related]
9. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771 [TBL] [Abstract][Full Text] [Related]
12. Targeting BRAFV600E in an inducible murine model of melanoma. Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458 [TBL] [Abstract][Full Text] [Related]
13. The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models. Yen J; White RM; Wedge DC; Van Loo P; de Ridder J; Capper A; Richardson J; Jones D; Raine K; Watson IR; Wu CJ; Cheng J; Martincorena I; Nik-Zainal S; Mudie L; Moreau Y; Marshall J; Ramakrishna M; Tarpey P; Shlien A; Whitmore I; Gamble S; Latimer C; Langdon E; Kaufman C; Dovey M; Taylor A; Menzies A; McLaren S; O'Meara S; Butler A; Teague J; Lister J; Chin L; Campbell P; Adams DJ; Zon LI; Patton EE; Stemple DL; Futreal PA Genome Biol; 2013; 14(10):R113. PubMed ID: 24148783 [TBL] [Abstract][Full Text] [Related]
14. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901 [TBL] [Abstract][Full Text] [Related]
15. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614 [TBL] [Abstract][Full Text] [Related]
16. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390 [TBL] [Abstract][Full Text] [Related]
17. Melanoma Cell Intrinsic GABA Pomeranz Krummel DA; Nasti TH; Kaluzova M; Kallay L; Bhattacharya D; Melms JC; Izar B; Xu M; Burnham A; Ahmed T; Li G; Lawson D; Kowalski J; Cao Y; Switchenko JM; Ionascu D; Cook JM; Medvedovic M; Jenkins A; Khan MK; Sengupta S Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):1040-1053. PubMed ID: 33289666 [TBL] [Abstract][Full Text] [Related]
18. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142 [TBL] [Abstract][Full Text] [Related]
19. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies. Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294 [TBL] [Abstract][Full Text] [Related]
20. Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. Kuczynski EA; Krueger J; Chow A; Xu P; Man S; Sundaravadanam Y; Miller JK; Krzyzanowski PM; Kerbel RS Mol Cancer Ther; 2018 Apr; 17(4):869-882. PubMed ID: 29483207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]